Declaration of Financial/Propriety Interest 2016

Ray Dingledine, Ph.D.

Research/Grants: National Institutes of Health (NIH)

Consulting (last three years): Covington and Burling LLC

Stockholder: Mutual funds, and NeurOp, Inc

Scientific Advisory Boards: The Epilepsy Project

Board of Directors: NeurOp, Inc.

Income sources or equity of $10,000 or more: None

Patents:
Cytotoxicity-based genetic selection system (TOXSEL), with Haian Fu and R. John Collier. US patent no. 5,733,726 issued 3/31/98.
pH-dependent NMDA receptor antagonists, with Steve Traynelis, Dennis Liotta, James Snyder, David Mott, James Doherty and Yesim Altus. US patent no. 7,375,136 issued May 20, 2008; WO 02/072542 A2
Improved Selection of pH-Dependent Compounds for In Vivo Therapy, with Steve Traynelis, Dennis Liotta. AU patent No. 2005277055 issued 14 July 2011; Japan patent no. 5015779 issued June 15, 2012.

Speakers
Bureau: None

Bjørnar Hassel, M.D., Ph.D.

Dr. Hassel has no conflicts of interest to report